Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wharton's jelly-derived mesenchymal stromal cells (AP-HP)
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Wharton's jelly-derived mesenchymal stromal cells (WJ-UC-MSC) are multipotent stem cells harvested from the mucoid connective tissue of the umbilical cord. Developed by Assistance Publique - Hôpitaux de Paris (AP-HP) for the treatment of severe traumatic brain injury (TBI), these cells are administered intravenously to leverage their potent immunomodulatory and neuroprotective properties. The therapeutic rationale is based on the cells' ability to migrate to sites of injury and secrete paracrine factors that modulate the systemic inflammatory response and reduce chronic neuroinflammation. By dampening the secondary injury cascade, the treatment aims to promote neurogenesis, angiogenesis, and functional neurological recovery in patients who remain unresponsive following the acute phase of brain trauma.
- Other names
- Wharton's Jelly-derived Mesenchymal Stromal CellsUmbilical Cord Wharton's Jelly-derived Mesenchymal Stem CellsTRAUMACELL
Beyond the preview
Go deeper on Wharton's jelly-derived mesenchymal stromal cells (AP-HP).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wharton's jelly-derived mesenchymal stromal cells (AP-HP).